Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis

NCT05445076 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Axial Spondyloarthritis

Interventions

BIOLOGICAL: anti-TRBV9 monoclonal antibody, low dose
BIOLOGICAL: anti-TRBV9 monoclonal antibody, high dose
OTHER: placebo

Sponsor

Biocad